10 likes | 180 Views
Role of Hematopoietic Growth Factors in the Prevention of Neutropenic Complications for Breast Cancer Patients Treated with Docetaxel, Doxorubicin, and Cyclophosphamide (TAC): Results of a Randomized Double-Blind Phase III Trial BCIRG 004.
E N D
Role of Hematopoietic Growth Factors in the Prevention of Neutropenic Complications for Breast Cancer Patients Treated with Docetaxel, Doxorubicin, and Cyclophosphamide (TAC): Results of a Randomized Double-Blind Phase III Trial BCIRG 004 John R. Mackey1, Jacques Cantin2, Jose Chang3, Raymond Guervin4, Ravi Patel5, Katherine Tkaczuk6, Pavel Vodvarka7, Michael Needle8, Thomas Peppard8, Jeffery Nieves8, Jean-Marc Nabholtz9, on behalf of the Breast Cancer International Research Group 1Cross Cancer Institute, Edmonton, AB, Canada; 2CHUM Campus Hotel Dieu, Montreal, QC, Canada; 3Oshawa general Hospital/Lakeridge Health Oshawa, Oshawa, ON, Canada; 4CHUM Pavillon Saint-Luc, Montreal, QC, Canada; 5Comprehensive Blood and Cancer Center, Bakersfield, CA; 6Greenebaum Cancer Centre, Baltimore, MD; 7FNsP Ostrava, Ostrava - Poruba, Czech Republic; 8Pharmacia, Skokie, IL; 9Univ. California at Los Angeles, CA.